Suicidal mutant Leishmania vaccine
US7238347B2 · kind B2 · utility
3Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2005 |
| Grant date | Jul 3, 2007 |
| Priority date | — |
| Expiry date | Mar 28, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses the use of a mutant Leishmania as a suicidal vaccine wherein the mutant Leishmania is responsive to external signals to become porphyric and commit suicidal cytolysis. The mutant can be selected from natural Leishmania species or constructed by genetic engineering.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.